AMGN Amgen Inc. Loading... : Bullish and Bearish Analyst Opinions
From COR earnings callsLoading chart...
Top Calls
Feed
12:30
Aug 05
Aug 05
Cencora management notes that biosimilar switches in Part D are causing revenue pressure but only marginal profit growth, whereas Part B switches provide significant upside due to the profitable wraparound services. — Indicates a significant pricing power shift and profit opportunity for Cencora as Part B biosimilar launches continue, and is a negative signal for innovator drug pricing power.
MED
About AMGN Analyst Coverage
Buzzberg tracks AMGN (Amgen Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Bob Mauch.